Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection

Journal of Immunology

Volumn 180, Issue 1, 2008, Pages 89-105

  Mariotti, Jacopo ^a   Foley, Jason ^a   Jung, Unsu ^a   Borenstein, Todd ^a   Kantardzic, Nermina ^a   Han, Soo ^a   Hanson, Joshua T ^a   Wong, Elaine ^a   Buxhoeveden, Nicole ^a   Trepel, Jane B ^a   Fojo, Antonio Tito ^a   Telford, William ^a   Fowler, Daniel H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE 3; CASPASE 9; CD28 ANTIGEN; CD3 ANTIGEN; FAS LIGAND; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; PERFORIN; PROTEIN BCL XL; PROTEIN BID; RAPAMYCIN; STAUROSPORINE; TRANSCRIPTION FACTOR FOXP3; APOPTOSIS REGULATORY PROTEIN; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; EX VIVO STUDY; GRAFT REJECTION; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; TH2 CELL; ANIMAL; CONGENIC STRAIN; DRUG EFFECT; GENETICS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CYTOKINES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, CONGENIC; PROTEIN KINASES; SIROLIMUS; TH2 CELLS;

EID: 40449100796     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.1.89     Document Type: Article

References (63)

1. Reisner, Y., I. Ben-Bassat, D. Douer, A. Kaploon, E. Schwartz, and B. Ramot. 1986. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc. Natl. Acad. Sci. USA 83: 4012-4015.
2. Murphy, W. J., V. Kumar, and M. Bennett. 1987. Acute rejection of murine bone marrow allografts by natural killer cells and T cells: differences in kinetics and target antigens recognized. J. Exp. Med. 166: 1499-1509.
3. Walshe, J., and M. R. Bishop. 2004. Factors affecting engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning. Cytotherapy 6: 589-602.
4. Petersdorf, E. W. 2004. HLA matching in allogeneic stem cell transplantation. Curr. Opin. Hematol. 11: 386-391.
5. Martin, P. J. 1993. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J. Exp. Med. 178: 703-712.
6. Martin, P. J., S. D. Rowley, C. Anasetti, T. R. Chauncey, T. Gooley, E. W. Petersdorf, J. A. van Burik, M. E. Flowers, R. Storb, F. R. Appelbaum, and J. A. Hansen. 1999. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 94: 2192-2199.
7. Martin, P. J. 1996. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism. Blood 88: 962-969.
8. + T cells of Tc2 phenotype potently inhibit marrow graft rejection. Blood 91: 4045-4050.
9. 1 T cells. Blood 94: 3212-3221.
10. Bachar-Lustig, E., S. Reich-Zeliger, and Y. Reisner. 2003. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood 102: 1943-1950.
11. Drobyski, W. R., H. C. Morse, III, W. H. Burns, J. T. Casper, and G. Sandford. 2001. Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. Blood 97: 2506-2513.
12. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104: 3804-3812.
13. + T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 105: 1828-1836.
14. + regulatory T cells. Proc. Natl. Acad. Sci. USA 103: 5460-5465.
15. Erdmann, A. A., U. Jung, J. E. Foley, Y. Toda, and D. H. Fowler. 2004. Costimulated/Tc2 cells abrogate murine marrow graft rejection. Biol. Blood Marrow Transplant. 10: 604-613.
16. Foley, J. E., U. Jung, A. Miera, T. Borenstein, J. Mariotti, M. Eckhaus, B. E. Bierer, and D. H. Fowler. 2005. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J. Immunol. 175: 5732-5743.
17. Jung, U., J. E. Foley, A. A. Erdmann, Y. Toda, T. Borenstein, J. Mariotti, and D. H. Fowler. 2006. Ex vivo rapamycin generates Th1/Tc1 and Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Biol. Blood Marrow Transplant. 9: 905-918.
18. Gattinoni, L., D. J. Powell, Jr., S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393.
19. + T cells exceeds that of an aggressively growing mouse tumor. Cancer Res. 66: 1132-1138.
20. Rathmell, J. C., E. A. Farkash, W. Gao, and C. B. Thompson. 2001. IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol. 167: 6869-6876.
21. Colombetti, S., V. Basso, D. L. Mueller, and A. Mondino. 2006. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J. Immunol. 176: 2730-2738.
22. L via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway. J. Immunol. 174: 180-194.
23. Castedo, M., K. F. Ferri, and G. Kroemer. 2002. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ. 9: 99-100.
24. L induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. J. Biol. Chem. 279: 910-191.
25. + T cells activated in a graft-versus-host reaction. J. Immunol. 145: 2167-2176.
26. Jung, U., J. E. Foley, A. A. Erdmann, M. A. Eckhaus, and D. H. Fowler. 2003. CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 102: 3439-3446.
27. + T cells. J. Exp. Med. 202: 907-912.
28. Goodell, M. A., K. Brose, G. Paradis, A. S. Conner, and R. C. Mulligan. 1996. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183: 1797-1806.
29. Chen, B. J., X. Cui, G. D. Sempowski, J. Domen, and N. J. Chao. 2004. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 103: 4344-4352.
30. Shizuru, J. A., I. L. Weissman, R. Kernoff, M. Masek, and Y. C. Scheffold. 2000. Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. Proc. Natl. Acad. Sci. USA 97: 9555-9560.
31. Pan, L., T. Teshima, G. R. Hill, D. Bungard, Y. S. Brinson, V. S. Reddy, K. R. Cooke, and J. L. Ferrara. 1999. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood 93: 4071-4078.
32. Ramsfjell, V., O. J. Borge, O. P. Veiby, J. Cardier, M. J. Murphy, Jr., S. D. Lyman, S. Lok, and S. E. Jacobsen. 1996. Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: distinct interactions with the ligands for c-kit and FLT3. Blood 88: 4481-4492.
33. Scaffidi, C., S. Fulda, A. Srinivasan, C. Friesen, F. Li, K. J. Tomaselli, K. M. Debatin, P. H. Krammer, and M. E. Peter. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17: 1675-1687.
34. Krueger, A., S. C. Fas, S. Baumann, and P. H. Krammer. 2003. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol. Rev. 193: 58-69.
35. Devadas, S., J. Das, C. Liu, L. Zhang, A. I. Roberts, Z. Pan, P. A. Moore, G. Das, and Y. Shi. 2006. Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity 25: 237-347.
36. Danial, N. N., and S. J. Korsmeyer. 2004. Cell death: critical control points. Cell 116: 205-219.
37. O'Connor, L., A. Strasser, L. A. O'Reilly, G. Hausmann, J. M. Adams, S. Cory, and D. C. Huang. 1998. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17: 384-395.
38. Wang, K., X. M. Yin, D. T. Chao, C. L. Milliman, and S. J. Korsmeyer. 1996. BID: a novel BH3 domain-only death agonist. Genes Dev. 10: 2859-2869.
39. Boise, L. H., M. Gonzalez-Garcia, C. E. Postema, L. Ding, T. Lindsten, L. A. Turka, X. Mao, G. Nunez, and C. B. Thompson. 1993. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608.
40. Bertrand, R., E. Solary, P. O'Connor, K. W. Kohn, and Y. Pommier. 1994. Induction of a common pathway of apoptosis by staurosporine. Exp. Cell Res. 211: 314-321.
41. Austin, M., and S. J. Cook. 2005. Increased expression of Mcl-1 is required for protection against serum starvation in phosphatase and tensin homologue on chromosome 10 null mouse embryonic fibroblasts, but repression of Bim is favored in human glioblastomas. J. Biol. Chem. 280: 33280-33288.
42. Arceci, R. J., K. Stieglitz, and B. E. Bierer. 1992. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 80: 1528-1536.
43. Sun, S. Y., L. M. Rosenberg, X. Wang, Z. Zhou, P. Yue, H. Fu, and F. R. Khuri. 2005. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65: 7052-7058.
44. Fox, C. J., P. S. Hammerman, R. M. Cinalli, S. R. Master, L. A. Chodosh, and C. B. Thompson. 2003. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 17: 1841-1854.
45. Fox, C. J., P. S. Hammerman, and C. B. Thompson. 2005. The Pim kinases control rapamycin-resistant T cell survival and activation. J. Exp. Med. 201: 259-266.
46. Beals, C. R., C. M. Sheridan, C. W. Turck, P. Gardner, and G. R. Crabtree. 1997. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275: 1930-1934.
47. Zhang, H. H., A. I. Lipovsky, C. C. Dibble, M. Sahin, and B. D. Manning. 2006. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell. 24: 185-197.
48. + regulatory T cells. Blood 105: 4743-4748.
49. Staruch, M. J., N. H. Sigal, and F. J. Dumont. 1991. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. Int. J. Immunopharmacol. 13: 677-685.
50. Wells, A. D., X. C. Li, Y. Li, M. C. Walsh, X. X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W. W. Hancock, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5: 1303-1307.
51. Sandalova, E., C. H. Wei, M. G. Masucci, and V. Levitsky. 2004. Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc. Natl. Acad. Sci. USA 101: 3011-3016.
52. Albert, M. H., X. Z. Yu, P. J. Martin, and C. Anasetti. 2005. Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. Blood 105: 1355-1361.
53. Teachey, D. T., D. A. Obzut, K. Axsom, J. K. Choi, K. C. Goldsmith, J. Hall, J. Hulitt, C. S. Manno, J. M. Maris, N. Rhodin, et al. 2006. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood 108: 1965-1971.
54. Sarbassov, D. D., S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, and D. M. Sabatini. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 22: 159-168.
55. Gross, A., J. M. McDonnell, and S. J. Korsmeyer. 1999. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13: 1899-1911.
56. Scheffold, C., Y. C. Scheffold, T. M. Cao, J. Gworek, and J. A. Shizuru. 2005. Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells. Biol. Blood Marrow Transplant. 11: 1-12.
57. + T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin- CD95L-, TNFR1-, and TRAIL-dependent killing. Blood 101: 3991-3999.
58. Jiang, Z., G. B. Adams, A. M. Hanash, D. T. Scadden, and R. B. Levy. 2002. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation. Biol. Blood Marrow Transplant. 8: 588-596.
59. Martin, P. J., Y. Akatsuka, M. Hahne, and G. Sale. 1998. Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood 92: 2177-2181.
60. Reich-Zeliger, S., J. Gan, E. Bachar-Lustig, and Y. Reisner. 2004. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model: II. deletion of effector cells by Fas-Fas ligand apoptosis. J. Immunol. 173: 6660-6666.
61. + T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J. Exp. Med. 202: 1549-1561.
62. Taylor, J. J., M. Mohrs, and E. J. Pearce. 2006. Regulatory T cell responses develop in parallel to Th responses and control the magnitude and phenotype of the Th effector population. J. Immunol. 176: 5839-5847.
63. + Tr cells. Blood 105: 1162-1169.